Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nu-Med Plus (NUMD) Cash & Equivalents (2016 - 2021)

Nu-Med Plus' Cash & Equivalents history spans 10 years, with the latest figure at $31840.0 for Q3 2021.

  • Quarterly results put Cash & Equivalents at $31840.0 for Q3 2021, up 1.09% from a year ago — trailing twelve months through Sep 2021 was $31840.0 (up 1.09% YoY), and the annual figure for FY2020 was $188506.0, up 2562.89%.
  • Cash & Equivalents for Q3 2021 was $31840.0 at Nu-Med Plus, down from $72831.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $409313.0 in Q3 2017 to a low of $6106.0 in Q2 2020.
  • The 5-year median for Cash & Equivalents is $139265.0 (2021), against an average of $148173.1.
  • The sharpest move saw Cash & Equivalents surged 29496.02% in 2017, then plummeted 95.77% in 2019.
  • Year by year, Cash & Equivalents stood at $351043.0 in 2017, then plummeted by 52.28% to $167513.0 in 2018, then plummeted by 95.77% to $7079.0 in 2019, then surged by 2562.89% to $188506.0 in 2020, then plummeted by 83.11% to $31840.0 in 2021.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $31840.0, $72831.0, and $139265.0 for Q3 2021, Q2 2021, and Q1 2021 respectively.